-

03:09:15 PM

XAIR Stock News

XAIR - Beyond Air Inc

10/03/22 7:30 AM

Nasdaq : XAIR

Beyond Air(R) Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary

RHEA-AI

neutral

09/16/22 4:05 PM

Nasdaq : XAIR

conferences

Beyond Air(R) To Participate in Three Upcoming Investor Conferences

Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary

RHEA-AI

neutral

08/23/22 8:00 AM

Nasdaq : XAIR

clinical trial

Beyond Air(R) Affiliate Beyond Cancer(TM) Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that the first patient was

RHEA-AI

neutral

08/11/22 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air(R) Reports Financial Results for the First Quarter of Fiscal Year 2023

Initiated U.S. commercial launch of LungFit(R) PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Will present data from the pilot study of at-home LungFit(R) GO for nontuberculous mycobacterial lung infection at the

RHEA-AI

positive

07/27/22 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air(R) Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory

RHEA-AI

neutral

06/28/22 4:10 PM

Nasdaq : XAIR

earnings

Beyond Air(R) Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

LungFit (R) PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit (R) PRO in hospitalized patients

RHEA-AI

positive

06/28/22 4:05 PM

Nasdaq : XAIR

fda approval

Beyond Air's LungFit(R) PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide Eliminates the need for traditional nitric oxide tanks from the hospital setting

RHEA-AI

neutral

06/14/22 4:30 PM

Nasdaq : XAIR

earnings

Beyond Air(R) Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

06/01/22 7:00 AM

Nasdaq : XAIR

management

Beyond Cancer(TM) Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practice in California.

RHEA-AI

very positive

05/17/22 4:05 PM

Nasdaq : XAIR

Beyond Air(R) Presents Positive Study Update from the At-Home LungFit(R) GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully titrated to receive the target 250 ppm NO regimen at home LungFit(R) GO is the first NO generator and

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

XAIR Data

IndustryOther Industrial Machinery Manufacturing
Websitewww.ait-pharm.com
CeoSteven Lisi
Security nameBeyond Air Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees23
Tags
- Technology Services
- Packaged Software
- Manufacturing
- Other Industrial Machinery Manufacturing
Address825 E Gate Blvd Ste 320
StateNew York
CityGarden City
Zip11530-2135
CountryUS
Phone15166658200

About Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.